# Filing Detail

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001962221-25-000003
Filing Date
2025-08-08
Accepted
2025-08-08 13:26:23
Documents
2

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | primary_doc.html | SCHEDULE 13D |
1 |  | primary_doc.xml | SCHEDULE 13D | 16694
2 | JOHN TEMPLETON FOUNDATION LETTER OF AUTHORIZATION | domaauthletter2.pdf | EX-24 | 688248
| Complete submission text file | 0001962221-25-000003.txt |  | 873477

Mailing Address 2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CA 94005 650-242-8052
Pacira BioSciences, Inc. (Subject) CIK: 0001396814 (see all company filings)

EIN.: 510619477 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-86096 | Film No.: 251197413
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3350 VIRGINIA STREET SUITE 530 MIAMI FL 33133
Business Address 3350 VIRGINIA STREET SUITE 530 MIAMI FL 33133 13055495081
Doma Perpetual Capital Management LLC (Filed by) CIK: 0001962221 (see all company filings)

EIN.: 880868808 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D